Becker's Spine Review

43 DEVICES & IMPLANTS Smith & Nephew selects Texas for $29M expansion project: 5 insights By Mackenzie Garrity S mith & Nephew chose its Fort Worth, Texas-based man- ufacturing plant as the location for a $29 million expansion project, according to the Dallas Business Journal. Here are five insights. 1. Smith & Nephew esti- mates 100 new jobs will be created as a result. The Fort Worth location currently employs around 200 people. 2. Matt Sober, president of Smith & Nephew's global operations, de- scribed the project as an effort to secure the com- pany's manufacturing process in the area. 3. Texas Enterprise Fund extended a $730,000 grant to Smith & Neph- ew to motivate the med- ical device company to choose Fort Worth. Com- peting locations included Oklahoma, Tennessee and Hull, England. 4. Smith and Nephew's advanced wound man- agement business is lo- cated at the Fort Worth plant. The team is filled with experts in wound care biotherapeutics. 5. Fort Worth Economic Development Depart- ment Director Robert Sturns noted the commu- nity's efforts and interests in biotech and medical innovation. n Paradigm Spine boosts leadership with 4 appointments — 6 takeaways By Megan Wood P aradigm Spine appointed four new people to its leadership team. Here are six takeaways. 1. e appointments include: • Francis Magee, DVM, as chief technol- ogy officer • Charlie Gilbride as executive vice presi- dent of sales and marketing • Tim Hein as vice president of sales • Lisa Denison as vice president of mar- keting 2. In his new role, Dr. Magee will head the product and technology development strat- egy and execution. Equipped with 25 years of experience in the orthopedic and spine device industry, Dr. Magee previously served as CTO for Orthologic, Spine Solutions and Synthes Spine. 3. Mr. Gilbride, Mr. Hein and Ms. Denison will oversee the marketing and sales efforts to boost adoption of the coflex Interlaminar Stabiliza- tion device in the U.S. e coflex is a posterior lumbar motion preservation solution designed to deliver pain relief and stability for patients with moderate to severe spinal stenosis. 4. Mr. Gilbride has 20-plus years of experi- ence in medical device sales, marketing and reimbursement. He previously served as vice president of U.S. product marketing for LDR Spine, which Zimmer Biomet acquired. 5. Mr. Hein has two decades of medical device industry experience, previously working at Zimmer Biomet Spine, LDR Spine, Medtron- ic, DePuy Spine and Ethicon Endo-Surgery. 6. Ms. Denison has more than 20 years of experience in the orthopedic and spine mar- keting and medical education landscape. Formerly, she worked at Sulzer Orthopedics, Abbott Spine and LDR Spine. n DePuy Synthes Q1 sales up 1.1%, spine drops 8.9% after Codman divestiture: 5 points By Laura Dyrda I n the first quarter of 2017, Johnson & Johnson reported their orthopedics business, DePuy Synthes, had a slight 1.1 percent growth over the same period last year. Here are five things to know. 1. The company's spine business sales had the largest decline, at 8.9 percent, reaching $804 mil- lion. Trauma sales were up 8.4 percent to $696 million. Hip sales grew 3.1 percent and knee sales dropped 2.8 percent to $363 million and $387 million, respec- tively. 2. Overall orthopedics sales hit $2.2 billion in the first quarter as the second largest sales group in the medical devices business line. The company's surgery line — which includes endocutters, biosurgery and energy — sales reached $2.4 billion with a 6.7 percent growth for the quarter. 3. Growth in hip sales was driv- en by leadership in the anterior approach and the ACTIS stem, offsetting flat U.S. sales. The com- pany attributed spine losses to its Codman divestiture and knee losses to the competitive pres- sure in the U.S. as well as declines in the EMEA markets. 4. U.S. orthopedics sales overall were down 3.8 percent in the first quarter while international sales were up 2.9 percent. The U.S. sales hit $1.3 billion. 5. The company's knee business reported 7.3 percent sales drop in the U.S., but 4.6 percent growth in international markets. n

• Cover